Compare BAFN & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAFN | ECOR |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6M | 39.6M |
| IPO Year | N/A | 2018 |
| Metric | BAFN | ECOR |
|---|---|---|
| Price | $8.00 | $4.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $25.50 |
| AVG Volume (30 Days) | 5.9K | ★ 57.5K |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $58,931,000.00 | $29,835,000.00 |
| Revenue This Year | N/A | $28.61 |
| Revenue Next Year | N/A | $41.21 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 27.90 |
| 52 Week Low | $6.40 | $4.16 |
| 52 Week High | $19.75 | $19.49 |
| Indicator | BAFN | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 37.72 | 44.41 |
| Support Level | $8.05 | $4.73 |
| Resistance Level | $8.07 | $5.11 |
| Average True Range (ATR) | 0.10 | 0.25 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 24.39 | 28.07 |
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.